Skip to main content
SpringerLink
Log in

TIPS Indications and Contraindications—Pushing the Limits: Is Earlier Better?

  • Management of Cirrhotic Patient (A Cardenas and P Tandon, Section Editors)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To describe the main indications and contraindications of transjugular intrahepatic portosystemic shunt (TIPS) placement in patients with portal hypertension (PH).

Recent Findings

An adequate selection of patients helps to identify those who may benefit from TIPS in terms of survival. In patients with acute variceal bleeding and factors of poor prognosis, a pre-emptive use of TIPS is associated with significant reductions in treatment failure and mortality. Similarly, TIPS has shown to improve survival in a highly selected group of patients with cirrhosis and refractory ascites.

Summary

PH is a clinical syndrome associated with the appearance of certain complications which can lead to high morbidity and mortality. TIPS placement effectively reduces portal pressure improving the outcomes of patients who present severe and/or refractory complications of PH. However, an adequate selection of candidates seems to be a key factor for improving the outcomes of patients treated with TIPS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–82. https://doi.org/10.1038/nrgastro.2009.149.

    Article  PubMed  CAS  Google Scholar 

  2. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–61. https://doi.org/10.1056/NEJMoa044456.

    Article  PubMed  CAS  Google Scholar 

  3. Ripoll C, Groszmann R, Garcia–Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481–8. https://doi.org/10.1053/j.gastro.2007.05.024.

    Article  PubMed  CAS  Google Scholar 

  4. Abraldes J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37:902–8. https://doi.org/10.1053/jhep.2003.50133.

    Article  PubMed  Google Scholar 

  5. Villanueva C, López-Balaguer JM, Aracil C, Kolle L, González B, Miñana J, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol. 2004;40:757–65. https://doi.org/10.1016/j.jhep.2004.01.017.

    Article  PubMed  Google Scholar 

  6. D’Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131:1611–24. https://doi.org/10.1053/j.gastro.2006.09.013.

    Article  PubMed  Google Scholar 

  7. Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126:469–75. https://doi.org/10.1053/j.gastro.2003.11.016.

    Article  PubMed  Google Scholar 

  8. Hernández-Guerra M, Turnes J, Rubinstein P, Olliff S, Elias E, Bosch J, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology. 2004;40:1197–202. https://doi.org/10.1002/hep.20436.

    Article  PubMed  Google Scholar 

  9. Thornburg B, Desai K, Hickey R, Kulik L, Ganger D, Baker T, et al. Portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: technical considerations. Tech Vasc Interv Radiol. 2016;19:52–60. https://doi.org/10.1053/j.tvir.2016.01.006.

    Article  PubMed  Google Scholar 

  10. Salem R, Vouche M, Baker T, Herrero JI, Caicedo JC, Fryer J, et al. Pretransplant portal vein recanalization—transjugular intrahepatic portosystemic shunt in patients with complete obliterative portal vein thrombosis. Transplantation. 2015;99:2347–55. https://doi.org/10.1097/TP.0000000000000729.

    Article  PubMed  Google Scholar 

  11. •• Thornburg B, Desai K, Hickey R, Hohlastos E, Kulik L, Ganger D, et al. Pretransplantation portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: final analysis of a 61-patient cohort. J Vasc Interv Radiol. 2017;28:1714–1721.e2. https://doi.org/10.1016/j.jvir.2017.08.005 This study analyzed the safety and efficacy of portal vein recanalization followed by TIPS in patients with cirrhosis and PVT as a procedure that aims to improve liver transplantation candidacy.

    Article  PubMed  Google Scholar 

  12. D’Amico G. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38:599–612. https://doi.org/10.1053/jhep.2003.50385.

    Article  PubMed  Google Scholar 

  13. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40:652–9. https://doi.org/10.1002/hep.20339.

    Article  PubMed  Google Scholar 

  14. Chau T, Patch D, Chan YW, Nagral A, Dick R, Burroughs AK. “Salvage” transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology. 1998;114:981–7. https://doi.org/10.1016/S0016-5085(98)00640-4.

    Article  PubMed  CAS  Google Scholar 

  15. Azoulay D, Castaing D, Majno P, Saliba F, Ichaï P, Smail A, et al. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol. 2001;35:590–7. https://doi.org/10.1016/S0168-8278(01)00185-4.

    Article  PubMed  CAS  Google Scholar 

  16. García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362:2370–9. https://doi.org/10.1056/NEJMoa0910102.

    Article  PubMed  Google Scholar 

  17. Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jiménez E, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology. 2004;40:793–801. https://doi.org/10.1002/hep.20386.

    Article  PubMed  Google Scholar 

  18. Garcia-Pagán JC, Di Pascoli M, Caca K, Laleman W, Bureau C, Appenrodt B, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013;58:45–50. https://doi.org/10.1016/j.jhep.2012.08.020.

    Article  PubMed  Google Scholar 

  19. Thabut D, Pauwels A, Carbonell N, Remy AJ, Nahon P, Causse X, et al. Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results. J Hepatol. 2018;68:73–81. https://doi.org/10.1016/j.jhep.2017.09.002.

    Article  Google Scholar 

  20. • Hernández-Gea V, Procopet B, Giráldez Á, Amitrano L, Villanueva C, Thabut D, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. Hepatology. 2018. https://doi.org/10.1002/hep.30182 This multicenter, international, observational study confirmed the survival benefit of TIPS in a large cohort of patients with cirrhosis and acute VB at high risk for treatment failure.

  21. Lv Y, Zuo L, Zhu X, Zhao J, Xue H, Jiang Z, et al. Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study. Gut. 2018:gutjnl-2018-317057. https://doi.org/10.1136/gutjnl-2018-317057.

  22. Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology. 1999;30:612–22. https://doi.org/10.1002/hep.510300316.

    Article  PubMed  CAS  Google Scholar 

  23. Khan SA, Tudur Smith C, Williamson PR, Sutton R. Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. Cochrane Database Syst Rev. 2006:CD000553. https://doi.org/10.1002/14651858.CD000553.pub2.

  24. de Franchis R. Expanding consensus in portal hypertension. J Hepatol. 2015;63:743–52. https://doi.org/10.1016/j.jhep.2015.05.022.

    Article  PubMed  Google Scholar 

  25. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–35. https://doi.org/10.1002/hep.28906.

    Article  PubMed  Google Scholar 

  26. Sauerbruch T, Mengel M, Dollinger M, Zipprich A, Rössle M, Panther E, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology. 2015;149:660–668.e1. https://doi.org/10.1053/j.gastro.2015.05.011.

    Article  PubMed  Google Scholar 

  27. Holster IL, Tjwa ETTL, Moelker A, Wils A, Hansen BE, Vermeijden JR, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding. Hepatology. 2016;63:581–9. https://doi.org/10.1002/hep.28318.

    Article  PubMed  CAS  Google Scholar 

  28. Garcia–Pagán JC, Patch D. Trials and tribulations: the prevention of variceal rebleeding. Gastroenterology. 2015;149:528–31. https://doi.org/10.1053/j.gastro.2015.07.026.

    Article  PubMed  Google Scholar 

  29. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003;38:69–89. https://doi.org/10.1016/S0168-8278(03)00007-2.

    Article  Google Scholar 

  30. Rössle M. TIPS: 25 years later. J Hepatol. 2013;59:1081–93. https://doi.org/10.1016/j.jhep.2013.06.014.

    Article  PubMed  Google Scholar 

  31. Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59:988–1000. https://doi.org/10.1136/gut.2009.193227.

    Article  PubMed  Google Scholar 

  32. •• Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152:157–63. https://doi.org/10.1053/j.gastro.2016.09.016 This study evaluates the use of TIPS using PTFE-covered stents in a selected population of patients with cirrhosis and refractory ascites.

    Article  PubMed  Google Scholar 

  33. Barange K, Péron J-M, Imani K, Otal P, Payen J-L, Rousseau H, et al. Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology. 1999;30:1139–43. https://doi.org/10.1002/hep.510300523.

    Article  PubMed  CAS  Google Scholar 

  34. Lo G-H, Liang H-L, Chen W-C, Chen M-H, Lai K-H, Hsu P-I, et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy. 2007;39:679–85. https://doi.org/10.1055/s-2007-966591.

    Article  PubMed  Google Scholar 

  35. Dhanasekaran R, West JK, Gonzales PC, Subramanian R, Parekh S, Spivey JR, et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol. 2010;105:635–41. https://doi.org/10.1038/ajg.2009.634.

    Article  PubMed  Google Scholar 

  36. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000;47:288–95. https://doi.org/10.1136/gut.47.2.288.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  37. Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology. 1998;28:416–22. https://doi.org/10.1002/hep.510280219.

    Article  PubMed  CAS  Google Scholar 

  38. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol. 2002;14:1363–8.

    Article  PubMed  CAS  Google Scholar 

  39. Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, et al. Changes in kidney function after transjugular intrahepatic portosystemic shunts versus large-volume paracentesis in cirrhosis: a matched cohort analysis. Am J Kidney Dis. 2016;68:381–91. https://doi.org/10.1053/j.ajkd.2016.02.041.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55–64. https://doi.org/10.1002/hep.20262.

    Article  PubMed  CAS  Google Scholar 

  41. Luca A, Caruso S, Milazzo M, Marrone G, Mamone G, Crinò F, et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology. 2012;265:124–32. https://doi.org/10.1148/radiol.12112236.

    Article  PubMed  Google Scholar 

  42. Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143:1253–1260.e4. https://doi.org/10.1053/j.gastro.2012.07.018.

    Article  PubMed  CAS  Google Scholar 

  43. Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol. 2013;108:568–74. https://doi.org/10.1038/ajg.2012.452.

    Article  PubMed  Google Scholar 

  44. Hibi T, Nishida S, Levi DM, Selvaggi G, Tekin A, Fan J, et al. When and why portal vein thrombosis matters in liver transplantation. Ann Surg. 2014;259:760–6. https://doi.org/10.1097/SLA.0000000000000252.

    Article  PubMed  Google Scholar 

  45. Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012;57:203–12. https://doi.org/10.1016/j.jhep.2011.12.034.

    Article  PubMed  Google Scholar 

  46. Ghabril M, Agarwal S, Lacerda M, Chalasani N, Kwo P, Tector AJ. Portal vein thrombosis is a risk factor for poor early outcomes after liver transplantation. Transplantation. 2016;100:126–33. https://doi.org/10.1097/TP.0000000000000785.

    Article  PubMed  CAS  Google Scholar 

  47. Urata J, Yamashita Y, Tsuchigame T, Hatanaka Y, Matsukawa T, Sumi S, et al. The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy. J Gastroenterol Hepatol. 1998;13:1061–7. https://doi.org/10.1111/j.1440-1746.1998.tb00571.x.

    Article  PubMed  CAS  Google Scholar 

  48. Kamath PS, Lacerda M, Ahlquist DA, McKusick MA, Andrews JC, Nagorney DA. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology. 2000;118:905–11. https://doi.org/10.1016/S0016-5085(00)70176-4.

    Article  PubMed  CAS  Google Scholar 

  49. Mezawa S, Homma H, Ohta H, Masuko E, Doi T, Miyanishi K, et al. Effect of transjugular intrahepatic portosystemic shunt formation on portal hypertensive gastropathy and gastric circulation. Am J Gastroenterol. 2001;96:1155–9. https://doi.org/10.1016/S0002-9270(01)02257-2.

    Article  PubMed  CAS  Google Scholar 

  50. European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64:179–202. https://doi.org/10.1016/j.jhep.2015.07.040.

    Article  Google Scholar 

  51. Perelló A, García-Pagán JC, Gilabert R, Suárez Y, Moitinho E, Cervantes F, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology. 2002;35:132–9. https://doi.org/10.1053/jhep.2002.30274.

    Article  PubMed  Google Scholar 

  52. Garcia–Pagán JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135:808–15. https://doi.org/10.1053/j.gastro.2008.05.051.

    Article  PubMed  Google Scholar 

  53. Seijo S, Plessier A, Hoekstra J, Dell’Era A, Mandair D, Rifai K, et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology. 2013;57:1962–8. https://doi.org/10.1002/hep.26306.

    Article  PubMed  Google Scholar 

  54. • Bissonnette J, Garcia-Pagán JC, Albillos A, Turon F, Ferreira C, Tellez L, et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatology. 2016;64:224–31. https://doi.org/10.1002/hep.28547 This retrospective study evaluates the efficacy and safety of TIPS in patients with idiopathic non-cirrhotic portal hypertension.

    Article  PubMed  Google Scholar 

  55. Siramolpiwat S, Seijo S, Miquel R, Berzigotti A, Garcia-Criado A, Darnell A, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology. 2014;59:2276–85. https://doi.org/10.1002/hep.26904.

    Article  PubMed  Google Scholar 

  56. Hernández-Gea V, Baiges A, Turon F, Garcia-Pagán JC. Idiopathic portal hypertension. Hepatology. 2018;68:2413–23. https://doi.org/10.1002/hep.30132.

    Article  PubMed  Google Scholar 

  57. Senzolo M, Tibbals J, Cholongitas E, Triantos CK, Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther. 2006;23:767–75. https://doi.org/10.1111/j.1365-2036.2006.02820.x.

    Article  PubMed  CAS  Google Scholar 

  58. Qi X, Han G, Yin Z, He C, Wang J, Guo W, et al. Transjugular intrahepatic portosystemic shunt for portal cavernoma with symptomatic portal hypertension in non-cirrhotic patients. Dig Dis Sci. 2012;57:1072–82. https://doi.org/10.1007/s10620-011-1975-5.

    Article  PubMed  Google Scholar 

  59. Fanelli F, Angeloni S, Salvatori FM, Marzano C, Boatta E, Merli M, et al. Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma. Dig Liver Dis. 2011;43:78–84. https://doi.org/10.1016/j.dld.2010.06.001.

    Article  PubMed  Google Scholar 

  60. Luo X, Nie L, Zhou B, Yao D, Ma H, Jiang M, et al. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension in noncirrhotic patients with portal cavernoma. Gastroenterol Res Pract. 2014;2014:1–8. https://doi.org/10.1155/2014/659726.

    Article  Google Scholar 

  61. Klinger C, Riecken B, Schmidt A, De Gottardi A, Meier B, Bosch J, et al. Transjugular portal vein recanalization with creation of intrahepatic portosystemic shunt (PVR-TIPS) in patients with chronic non-cirrhotic, non-malignant portal vein thrombosis Transjuguläre Pfortaderrekanalisation mit intrahepatischem portosystemischem. Z Gastroenterol. 2018;56:221–37. https://doi.org/10.1055/s-0043-121348.

    Article  PubMed  Google Scholar 

  62. Azoulay D, Castaing D, Lemoine A, Hargreaves GM, Bismuth H. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant. 2000;25:987–92. https://doi.org/10.1038/sj.bmt.1702386.

    Article  PubMed  CAS  Google Scholar 

  63. Campos-Varela I, Castells L, Dopazo C, Pérez-Lafuente M, Allende H, Len O, et al. Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. Liver Transpl. 2012;18:201–5. https://doi.org/10.1002/lt.22351.

    Article  PubMed  Google Scholar 

  64. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology. 2005;41:386–400. https://doi.org/10.1002/hep.20559.

    Article  PubMed  Google Scholar 

  65. Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–46. https://doi.org/10.1111/j.1572-0241.2008.02102.x.

    Article  PubMed  Google Scholar 

  66. Bai M, Qi X, Yang Z, Yin Z, Nie Y, Yuan S, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol. 2011;26:943–51. https://doi.org/10.1111/j.1440-1746.2011.06663.x.

    Article  PubMed  Google Scholar 

  67. Wang Q, Lv Y, Bai M, Wang Z, Liu H, He C, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. J Hepatol. 2017;67:508–16. https://doi.org/10.1016/j.jhep.2017.05.006.

    Article  PubMed  Google Scholar 

  68. Stents P, Miraglia R, Maruzzelli L, Amico MD, Luca A, Tuzzolino F, et al. Portosystemic shunts in patients with cirrhosis with refractory ascites: comparison of clinical outcomes by using 8- and 10-mm. Radiology. 2017;284:281–8. https://doi.org/10.1148/radiol.2017161644.

    Article  Google Scholar 

  69. Moitinho E, Escorsell À, Bandi J, Salmerón J, García–Pagán J, Rodés J, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999;117:626–631. doi:https://doi.org/10.1016/S0016-5085(99)70455-5.

  70. Bambha K, Kim WR, Pedersen R, Bida JP, Kremers WK, Kamath PS. Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut. 2008;57:814–20. https://doi.org/10.1136/gut.2007.137489.

    Article  PubMed  CAS  Google Scholar 

  71. Lecleire S, Di Fiore F, Merle V, Hervé S, Duhamel C, Rudelli A, et al. Acute upper gastrointestinal bleeding in patients with liver cirrhosis and in noncirrhotic patients: epidemiology and predictive factors of mortality in a prospective multicenter population-based study. J Clin Gastroenterol. 2005;39:321–7. https://doi.org/10.1097/01.mcg.0000155133.50562.c9.

    Article  PubMed  Google Scholar 

  72. Ripoll C, Bañares R, Rincón D, Catalina M-V, Lo Iacono O, Salcedo M, et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era. Hepatology. 2005;42:793–801. https://doi.org/10.1002/hep.20871.

    Article  PubMed  Google Scholar 

  73. Thomopoulos K, Theocharis G, Mimidis K, Lampropoulou-Karatza C, Alexandridis E, Nikolopoulou V. Improved survival of patients presenting with acute variceal bleeding. Prognostic indicators of short- and long-term mortality. Dig Liver Dis. 2006;38:899–904. https://doi.org/10.1016/j.dld.2006.08.002.

    Article  PubMed  CAS  Google Scholar 

  74. Avgerinos A, Armonis A, Stefanidis G, Mathou N, Vlachogiannakos J, Kougioumtzian A, et al. Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. Hepatology. 2004;39:1623–30. https://doi.org/10.1002/hep.20236.

    Article  PubMed  Google Scholar 

  75. Reverter E, Tandon P, Augustin S, Turon F, Casu S, Bastiampillai R, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology. 2014;146:412–419.e3. https://doi.org/10.1053/j.gastro.2013.10.018.

    Article  PubMed  Google Scholar 

  76. Bureau C, Métivier S, D’Amico M, Péron JM, Otal P, Pagan JCG, et al. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol. 2011;54:901–7. https://doi.org/10.1016/j.jhep.2010.08.025.

    Article  PubMed  CAS  Google Scholar 

  77. Chalasani N, Clark WS, Martin LG, Kamean J, Khan MA, Patel NH, et al. Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology. 2000;118:138–44. https://doi.org/10.1016/S0016-5085(00)70422-7.

    Article  PubMed  CAS  Google Scholar 

  78. Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2009;104:2458–66. https://doi.org/10.1038/ajg.2009.321.

    Article  PubMed  Google Scholar 

  79. Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut. 2003;52:879–85. https://doi.org/10.1136/gut.52.6.879.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Financial Support

This work was sponsored by the Instituto de Salud Carlos III (ISCIII) PI14/00182 and PI17/00298 and the European Union (Fondos FEDER, “Una manera de hacer Europa”). CIBERehd is funded by Instituto de Salud Carlos III.

Author information

Authors and Affiliations

  1. Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic de Barcelona, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Villarroel 170, 08036, Barcelona, Spain

    José Ferrusquía-Acosta & Virginia Hernández-Gea

  2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain

    Virginia Hernández-Gea

Authors
  1. José Ferrusquía-Acosta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Virginia Hernández-Gea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Virginia Hernández-Gea.

Ethics declarations

Conflict of Interest

José Ferrusquía-Acosta reports personal fees from GORE, outside the submitted work.

Virginia Hernández-Gea reports personal fees from GORE, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Management of Cirrhotic Patient

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferrusquía-Acosta, J., Hernández-Gea, V. TIPS Indications and Contraindications—Pushing the Limits: Is Earlier Better?. Curr Hepatology Rep 18, 87–95 (2019). https://doi.org/10.1007/s11901-019-00453-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-019-00453-5

Keywords

Search

Navigation